Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia

• Status: Completed
• Trial end date: 2020-03-09
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the safety and efficacy of humanized Meplazumab for Injection in patients infected by 2019-nCoA.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tang-Du Hospital

Criteria

Inclusion Criteria:

• Men and women aged 18 to 75 years (inclusive)

• In line with the new coronavirus infection pneumonia diagnosis and treatment plan (trial version 4) issued by the Health Commission, patients with new coronavirus (2019 ncov) pneumonia were clinically diagnosed;

• The subjects must be able to understand the study and willing to participate in the study, and sign the informed consent (if the subjects with no behavioral ability think it is in their own interests to participate in the test, they should sign the informed consent by their legal guardian, or notify the consent by phone (recording) and explain it in the original medical record and other relevant documents).

Exclusion Criteria:

• Known or expected to have allergic reactions or a history of allergy to any of the ingredients treated in this trial;

• In the judgment of the investigator, there are other reasons that the patient is not suitable to participate in this study.